Oncology Corporate Profile
Tocagen Inc. is a privately funded, clinical stage biopharmaceutical company pursuing the discovery, development and commercialization of gene therapy products for the selective treatment of cancer. Tocagen is initially focusing on treatments for patients with advanced cancer for whom no adequate treatments currently exist.
Website: http://www.tocagen.com
| Brand / Product | Class | Area of Study | Phase | Partnership |
|---|---|---|---|---|
| Toca 511 (+ Toca FC) | retroviral replicating vector | Brain Metastases from Breast cancer | Preclinical | |
| Toca 511 (+ Toca FC) | retroviral replicating vector | Brain Metastases from Non Small Cell Lung Cancer (NSCLC) | Preclinical | |
| Toca 511 (+ Toca FC) | retroviral replicating vector | Colorectal cancer | Preclinical | |
| Toca 511 (+ Toca FC) | retroviral replicating vector | Glioblastoma Multiforme (GBM) | Preclinical | |
| Toca 511 (+ Toca FC) | retroviral replicating vector | Melanoma | Preclinical | |
| Toca 511 (+ Toca FC) | retroviral replicating vector | Renal cell carcinoma (RCC) | Preclinical |
View additional information on product candidates here »
